Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
West's own designs earn nearly all the profit
Proprietary components earn far more per dollar than contract work, so each shift in sales mix moves profit more than sales.
For investorsWhat the proprietary margin depends on from here
For foundersHow a component maker turns one design win into years of sales
Of the 9.75-point rise in operating margin, 6.71 points came from one line, mainly the gain on selling SmartDose to AbbVie.
Cost of goods rose 3.3% while sales rose 8.7%, so most of each new sales dollar reached gross profit.
Capital spending took 20.6% of operating cash against 32.1% a year earlier, which more than offset weaker cash from operations.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes West Pharmaceutical Services from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
